Highest-materiality recent filing
CMS final payment rate of $854 per test set (Dec 2025) for both Epi+Gen CHD (0439U) and PrecisionCHD (0440U) CPT codes.
Cardio Diagnostics holds investor call; highlights $854 CMS rate, new CLIA lab, and India expansion
Investor presentation reveals $854 final CMS gapfill rate for both Epi+Gen CHD and PrecisionCHD tests.
Shareholders approve 20%+ share issuance authority, elect 7 directors at annual meeting
Elected 7 directors: Dogan, Hosseinion, Betts, Burton, Fung, Intrater, Philibert each with over 355K votes for.
Cardio Diagnostics regains Nasdaq minimum bid price compliance
On May 28, 2025, Nasdaq confirmed compliance after closing bid price ≥$1.00 for 10 consecutive business days (May 13-27, 2025).
Cardio Diagnostics announces 1-for-30 reverse stock split to regain Nasdaq compliance
Reverse split at 1:30, effective after close May 12; trading begins May 13 under CDIO.
Cardio Diagnostics provides investor presentation; no material new facts disclosed
Company filed an Investor Presentation dated February 2025 under Item 7.01.
Second Nasdaq letter grants 180-day extension until June 2, 2025, to meet $1.00 minimum bid price.
All seven director nominees elected: Dogan, Philibert, Burton, Hosseinion, Intrater, Betts, Fung.
Received Nasdaq notice on June 3, 2024 for non-compliance with minimum bid price rule (below $1.00 for 30 consecutive days).
Cardio Diagnostics releases March 2024 investor presentation for use with investors
Investor presentation becomes effective April 3, 2024.
Gross proceeds of $1,000,000 from sale of 561,793 units to 7 accredited investors at $1.78 per unit.
Cardio Diagnostics enters $17M at-the-market equity offering with Craig-Hallum
Up to $17M in common stock may be sold via Craig-Hallum as sales agent under an ATM offering.
Cardio Diagnostics terminates $11.2M convertible debenture agreement with Yorkville
Mutual termination of Securities Purchase Agreement effective Jan 4, 2024; no fees or penalties due.
Cardio Diagnostics shareholders approve reverse stock split, share issuance, and board
All seven director nominees elected; each received >5.8M for, <0.4M withheld, 3.48M broker non-votes.
Cardio Diagnostics regains Nasdaq minimum bid price compliance
Received Nasdaq notice on Dec 5, 2023 confirming compliance with minimum bid price rule.
Cardio Diagnostics receives Nasdaq equity deficiency notice; claims cure via Yorkville conversion
Nasdaq notified CDIO on Nov 20, 2023 of non-compliance with $2.5M minimum stockholders' equity requirement.
Cardio Diagnostics receives Nasdaq minimum bid price deficiency notice
Received Nasdaq notice on Sept 21, 2023 for common stock bid price below $1.00 for 30 consecutive business days.
Cardio Diagnostics extends Yorkville second closing to Dec 2023; lowers floor price to $0.20
Second closing deadline extended to December 29, 2023 from September 15, 2023, subject to conditions.
Cardio Diagnostics posts investor presentation; no specific updates disclosed
Senior management will use the new investor presentation starting September 11, 2023.
Agreements with James Intrater, Stanley Lau, Oded Levy, and Brandon Sim, effective June 19, 2023.
Cardio Diagnostics amends SPA with Yorkville, extends second closing to Sept 15, 2023
Amendment delays second closing of $6.2M convertible debenture from prior date to September 15, 2023.
Stockholders approve issuance of up to 20.4M shares upon conversion of $11.2M debentures to YA II PN
Share issuance could exceed 20% of outstanding common stock and be priced below Nasdaq Minimum Price.
Cardio Diagnostics begins using May 2023 investor presentation; no financial details disclosed
Senior management will use the presentation for meetings with investors effective May 16, 2023.
Gross proceeds up to $11.2M from YA II PN, Ltd. (Yorkville); first tranche $5M debenture at 90% ($4.5M), second $6.2M upon SEC reg. effectiveness.
Cardio Diagnostics dismisses auditor MaloneBailey, appoints Prager Metis CPAs
Dismissed MaloneBailey as independent auditor on November 9, 2022; no disagreements or reportable events in prior periods.
Cardio Diagnostics completes SPAC merger with Mana Capital; begins trading as CDIO, CDIOW
Mana stockholders approved merger on Oct 25; Business Combination closed same day, Legacy Cardio becomes subsidiary.
Mana Capital extends business combo deadline to Oct 26, 2022 with $216,667 loan from Cardio
Second one-month extension from Sept 26 to Oct 26, 2022, with up to 12 extensions permitted.
Cardio Diagnostics secures U.S. patent for cardiovascular disease detection technology
U.S. Patent No. 11,414,704 issued by USPTO to University of Iowa Research Foundation (UIRF), exclusively licensed to Cardio Diagnostics.
Amendment dated September 15, 2022 increases shares reserved under Cardio Diagnostics Holdings 2022 Incentive Plan to 3,265,516.
Mana Capital provides investor presentation for proposed Cardio Diagnostics merger
Investor presentation first made available on August 26, 2022, for the business combination with Cardio Diagnostics.
Mana Capital extends SPAC deadline to Sept 26 with $216,667 loan from Cardio Diagnostics
Extended deadline to complete initial business combination from Aug 26 to Sept 26, 2022.
Mana Capital SPAC to merge with Cardio Diagnostics in deal valuing target at $75M base
Cardio stockholders to receive shares of Mana Capital common stock valued at $10.00/share; base consideration $75M.
Mana Capital Acquisition Corp. switches auditor from Marcum to MaloneBailey
Dismissed Marcum Bernstein Pinchuk as auditor effective January 19, 2022, and engaged MaloneBailey same day.
Mana Capital Acquisition Corp. units separate into stock, warrants, rights starting Jan 14, 2022
Holders of the 6,500,000 IPO units may elect to separate components starting January 14, 2022.
Mana Capital Acquisition Corp. closes IPO and partial over-allotment, $65M in trust
IPO of 6,200,000 units at $10.00/unit, gross proceeds of $62,000,000.
Mana Capital Acquisition Corp. closes IPO and private placement, raising $64.5M
IPO of 6.2M units at $10 each generated gross proceeds of $62M.
Mana Capital Acquisition Corp. closes $62M IPO and $2.5M private placement
Gross proceeds of $62M from IPO of 6.2M units at $10.00 each; units trade on Nasdaq under MAAQU.
On the date of the Closing, and in accordance with the terms of the Merger Agreement, the Board became comprised of seven directors: Warren Hosseinion, MD, Meeshanthini (Meesha) Dogan, PhD, Robert Philibert, MD PhD, Brandon Sim, Stanley K. Lau, MD, Oded Levy and James Intrater.
On the date of the Closing, and in accordance with the terms of the Merger Agreement, the Board became comprised of seven directors: Warren Hosseinion, MD, Meeshanthini (Meesha) Dogan, PhD, Robert Philibert, MD PhD, Brandon Sim, Stanley K. Lau, MD, Oded Levy and James Intrater.
Allan Liu and Loren Mortman also resigned as members of the Board of Directors, effective as of the Closing.
On the date of the Closing, and in accordance with the terms of the Merger Agreement, the Board became comprised of seven directors: Warren Hosseinion, MD, Meeshanthini (Meesha) Dogan, PhD, Robert Philibert, MD PhD, Brandon Sim, Stanley K. Lau, MD, Oded Levy and James Intrater.
Immediately following the consummation of the Business Combination, the following individuals became the executive officers of the Company: Meeshanthini Dogan as Chief Executive Officer; Robert Philibert as Chief Medical Officer; Elisa Luqman as Chief Financial Officer; Timur Dogan as Chief Technology Officer and Khullani Abdullahi as Vice President of Revenue and Strategy.
Immediately following the consummation of the Business Combination, the following individuals became the executive officers of the Company: Meeshanthini Dogan as Chief Executive Officer; Robert Philibert as Chief Medical Officer; Elisa Luqman as Chief Financial Officer; Timur Dogan as Chief Technology Officer and Khullani Abdullahi as Vice President of Revenue and Strategy.
Immediately following the consummation of the Business Combination, the following individuals became the executive officers of the Company: Meeshanthini Dogan as Chief Executive Officer; Robert Philibert as Chief Medical Officer; Elisa Luqman as Chief Financial Officer; Timur Dogan as Chief Technology Officer and Khullani Abdullahi as Vice President of Revenue and Strategy.
On the date of the Closing, and in accordance with the terms of the Merger Agreement, the Board became comprised of seven directors: Warren Hosseinion, MD, Meeshanthini (Meesha) Dogan, PhD, Robert Philibert, MD PhD, Brandon Sim, Stanley K. Lau, MD, Oded Levy and James Intrater.
Effective as of the Closing of the Business Combination, Jonathan Intrater resigned as Chairman of the Board, Chief Executive Officer and Chief Financial Officer of the Company.
Immediately following the consummation of the Business Combination, the following individuals became the executive officers of the Company: Meeshanthini Dogan as Chief Executive Officer; Robert Philibert as Chief Medical Officer; Elisa Luqman as Chief Financial Officer; Timur Dogan as Chief Technology Officer and Khullani Abdullahi as Vice President of Revenue and Strategy.
On the date of the Closing, and in accordance with the terms of the Merger Agreement, the Board became comprised of seven directors: Warren Hosseinion, MD, Meeshanthini (Meesha) Dogan, PhD, Robert Philibert, MD PhD, Brandon Sim, Stanley K. Lau, MD, Oded Levy and James Intrater.
Immediately following the consummation of the Business Combination, the following individuals became the executive officers of the Company: Meeshanthini Dogan as Chief Executive Officer; Robert Philibert as Chief Medical Officer; Elisa Luqman as Chief Financial Officer; Timur Dogan as Chief Technology Officer and Khullani Abdullahi as Vice President of Revenue and Strategy.
Max materiality 0.80 · Median 0.55 · Most common event other_material